CT can provide faster, easier-to-capture evidence of non-alcoholic fatty liver disease than MRI or ultrasound elastography.
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of liver disease worldwide, and multi-parametric CT can be an effective way for providers to identify which patients have the condition.
With NAFLD affecting roughly 25 percent of adults across the globe – and nearly a quarter of those individuals progressing on to non-alcoholic steatohepatitis (NASH), a precursor to cirrhosis – finding a strategy that can pinpoint patients who could benefit from treatment is critical.
In an article published Jan. 22 in the American College of Roentgenology, a team of investigators from the University of Wisconsin outlined the CT parameters that enable non-invasive NAFLD detection. They also presented their results during the American Roentgen Ray Society (ARRS) 2019 annual meeting.
Related Content: MRI Technique Can Estimate Liver Fat in Children
“CT is a highly accessible, frequently used method for assessment of patients with NAFLD and identification of those with high-risk NAFLD (advanced fibrosis or cirrhosis) who are potentially most in need of intervention,” said the team led by Meghan G. Lubner, M.D., professor of radiology in the abdominal imaging section at Wisconsin.
True-positive assessments in 58-year-old woman with high-risk nonalcoholic fatty liver disease (NAFLD) and associated NASH. CT images show hepatic enlargement, heterogeneously low-attenuation hepatic parenchyma, and surrounding ascites. Readers correctly identified NASH according to these imaging features. Readers also correctly identified fibrosis stage F3. Courtesy: American Journal of Roentgenology
True-positive assessments in 52-year-old man with high-risk nonalcoholic fatty liver disease (NAFLD) and associated NASH. CT images show hepatic enlargement, heterogeneously low-attenuation hepatic parenchyma, and surrounding ascites. Readers correctly identified NASH according to these imaging features. Readers also correctly identified fibrosis stage F3. Courtesy: American Journal of Roentgenology
The use of multi-parametric CT fills a void, the team said. Both MR and ultrasound elastography techniques has been successful in measuring liver stiffness as a surrogate for fibrosis. But, they come with obstacles – not only do they require a significant level of expertise, but they also are not used much in the clinical setting. In contrast, non-invasive CT biomarkers are frequently used clinically to diagnose liver disease and hepatic fibrosis.
For this study, Lubner’s team focused specifically on identifying patients with high-risk NAFLD. In a single-institution retrospective cohort study, they looked at CT images captured on 16-to-64-MDCT scanners within a year of liver biopsy from 186 patients with the condition. Most images were contrast-enhanced.
False-positive assessments in 73-year-old woman with high-risk NAFLD but without pathologic evidence of NASH. CT images show findings similar to A and B. Readers incorrectly identified NASH because of these imaging findings but correctly identified fibrosis stages F3. Courtesy: American Journal of Roentgenology
False-positive assessments in 61-year-old woman with high-risk NAFLD but without pathologic evidence of NASH. CT images show findings similar to A and B. Readers incorrectly identified NASH because of these imaging findings but correctly identified fibrosis stages F4. Courtesy: American Journal of Roentgenology
Of the group, 87 individuals had NASH, and 112 had moderate-to-severe steatosis. For fibrosis stages, 51 were F0, 42 were F1, 23 were F2, 37 were F3, and 33 were F4. A group of 70 individuals – 38 percent – had advanced fibrosis and high-risk NAFLD.
Based on the team’s analysis, the Fibrosis-4 (FIB-4) index score correlated with fibrosis with ROC AUC of 0.75 for identifying high-risk NAFLD. In addition, the CT parameters liver segmental volume ratio and splenic volume performed best – they both had an AUC of 0.69 for detection of the condition.
“Patients with a high FIB-4 score and CT findings of advanced fibrosis may no longer need biopsy for confirmation,” the team said. “Therefore, use of FIB-4 and CT together may reduce the need for invasive testing.”
Overall, however, they explained, reader assessment – a subjective cognitive combination of the measured features by trained readers – was the highest performing parameter with an AUC of 0.78 and 0.79 for both readers. Performance by the readers revealed a good association with the presence of advanced fibrosis.
While CT performed well for NAFLD detection, it was underwhelming for picking up on evidence of NASH. According to the team, all single imaging parameters, including subjective reader assessment, performed poorly.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.